GE Healthcare Financial Services: Debt Financing and the Importance of IP




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: GE Healthcare Financial Services: Debt Financing and the Importance of IP
Released on: December 01, 2007. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this exclusive interview, Fintan Walton talks to Marcus O’Neill, VP Life Science Finance at GE Healthcare Financial Services.
  • Summary
  • Participants
  • Company
In this exclusive interview, Fintan Walton talks to Marcus O’Neill, VP Life Science Finance at GE Healthcare Financial Services. The topic of this week’s discussion is debt financing, or ‘venture debt’, as it is also known. Marcus talks through the structure of this type of lending, particularly in the case of early-stage companies. He emphasises the need for companies to have backing from good quality venture capital funding, long-term future value and assigned IP, and draws on Astex Therapeutics and Arrow Therapeutics as examples of high-profile recipients of debt financing.
Marcus O’Neill

After qualifying with an MBA from Kingston University, Marcus joined GE from Citigroup, where he worked within Business Development for Citigroup’s vendor leasing business. He holds an Honours degree in Business Studies from Manchester Metropolitan University, a postgraduate diploma in Marketing and a Finance House Diploma. At GE, Marcus specialises in providing venture debt finance to the biotechnology and medical technology sectors across Europe.
GE Healthcare Financial Services